Deloitte appoints Robert Hillard as Asia Pacific Chief Executive Officer

1 Jun 2026, 1:00 am

Traveloka 6.6 Mid Year Sale: Up to S$66 Off Flights, Hotels and Attractions for Singapore Travelers

1 Jun 2026, 1:00 am

Calibrite Display Plus HL Receives Apple Approval for Hardware-Level Display Calibration

1 Jun 2026, 1:00 am

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

1 Jun 2026, 12:15 am

Long-term Follow-up Results of CARsgen’s Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

1 Jun 2026, 12:15 am

AMD Bundles Carbice Ice Pad with Ryzen™ 7 5800X3D

1 Jun 2026, 12:00 am

New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026

1 Jun 2026, 12:00 am

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

1 Jun 2026, 12:00 am

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

1 Jun 2026, 12:00 am

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

1 Jun 2026, 12:00 am

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

1 Jun 2026, 12:00 am

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment’s Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

1 Jun 2026, 12:00 am

Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders

1 Jun 2026, 12:00 am

United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026

31 Mei 2026, 3:00 pm

BLUETTI Launches EOFY Sale on Power Solutions with Up to 44% OFF

31 Mei 2026, 2:00 pm

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

31 Mei 2026, 1:00 pm

Relief as Firmable locates 15,000 accounting decision-makers reported missing at leading global B2B data provider

31 Mei 2026, 12:57 pm

AI: Digital to Physical | BEYOND Expo 2026 Leads Transformative Global Direction of Tech

31 Mei 2026, 6:32 am